Hepatocellular carcinoma peritoneal metastases: report of three cases and collective review of the literature.
- Author:
Jesslyn H DING
1
;
Terence C CHUA
;
Khalid AL-MOHAIMEED
;
David L MORRIS
Author Information
- Publication Type:Case Reports
- MeSH: Carcinoma, Hepatocellular; drug therapy; pathology; surgery; Fatal Outcome; Female; Humans; Liver Neoplasms; drug therapy; pathology; surgery; Male; Middle Aged; Peritoneal Neoplasms; drug therapy; secondary; surgery; Peritoneum; pathology; Young Adult
- From:Annals of the Academy of Medicine, Singapore 2010;39(9):734-734
- CountrySingapore
- Language:English
-
Abstract:
INTRODUCTIONPatients with peritoneal metastases (PM) from hepatocellular carcinoma (HCC) often experience a rapid demise even after a complete removal of intrahepatic tumour. Localised PM may now be adequately controlled and managed with cytoreductive surgery (CRS).
TREATMENTThree patients underwent CRS for HCC PM.
OUTCOMEThe first patient survived 21 months from the time of CRS and is alive with the disease. The second patient died 4 months after CRS. The third patient survived 10 months since CRS and is also alive with the disease. Collectively, the survival of 24 patients with HCC PM extracted through a collective literature review who were treated with cytoreductive surgery had 1- and 2-year survival percentages of 83% and 71%, respectively.
CONCLUSIONCareful selection of patients with localised disease to the peritoneal cavity for CRS, taking into consideration the performance status, liver function and tumour biology may lead to a successful outcome in patients with HCC PM.
